Sclerostin Binding Agents

Patent No. EP2325199 (titled "Sclerostin Binding Agents") was filed by Amgen on Apr 28, 2006. The application was issued on Mar 4, 2015.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JAMES POOLEDec 3, 2015CARPMAELS & RANSFORD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2325199

AMGEN
Application Number
EP10014362A
Filing Date
Apr 28, 2006
Status
Revoked
Mar 14, 2022
Publication Date
Mar 4, 2015